MRO Releases 2026 State of the Industry Report
Report examines policy disruption, market pressures, and how smarter use of clinical data can drive resilience, trust, and growth
Drawing on original survey data from healthcare executives and consumers, as well as policy and market analysis, the report explores the ripple effects of sweeping legislative changes, including the One Big Beautiful Bill Act (OBBBA), heightened regulatory enforcement around interoperability and privacy, funding uncertainty for research, and rising cost pressures tied to tariffs. Together, these forces are redefining how healthcare organizations fund, deliver, and sustain care in 2026 and beyond.
"The healthcare industry is entering a pivotal moment," said
Key insights from the report include:
- Policy and financial pressure are accelerating change. Healthcare leaders expect the OBBBA to significantly impact Medicaid revenue and operating margins, with 72% expressing concern about its organizational impact. Many are already revising care delivery models and operational strategies in response.
- Interoperability and enforcement are intensifying. CMS and HHS are placing renewed emphasis on data sharing, privacy, and patient access — backed by increased enforcement activity. An industry survey found that nearly one-third of health IT leaders cite fragmented systems as a major barrier to interoperability, underscoring the need for secure, centralized clinical data management.
- Value-based care continues to expand. More than 60% of healthcare organizations increased participation in value-based care programs in 2025, and 28% of hospital and health system leaders plan to expand further in response to policy and financial pressures. Reliable, high-quality clinical data remains the foundation for success.
- Patients are worried about affordability and quality. Nearly two-thirds of consumers surveyed expressed concern about rising out-of-pocket costs tied to tariffs, and 74% believe these pressures could affect their provider's ability to deliver quality care — perceptions that may influence care-seeking behavior and loyalty.
Across each of these challenges, the report points to clinical data as the common denominator for resilience, with 81% of organizations planning to use clinical data to inform or assess the strategies they are considering. From powering value-based care and reducing administrative burden, to enabling new research pathways and strengthening patient trust, smarter use of clinical data allows organizations to make informed decisions amid volatility.
"As healthcare leaders plan for what comes next, data will be the difference between reactive change and intentional strategy," added
The 2026 State of the Industry report is available now. Read the full report here.
About MRO
MRO is The Single Source for Smarter Data™—driving a new era of clinical data intelligence where data is connected, structured, and transformed into actionable insights. The result: confident decisions, operational precision, accelerated research, and most importantly, better patient care.
This innovative model for clinical data management is built for speed and scale, combining FHIR-native connectivity, deep clinical expertise, and advanced automation to turn a fragmented healthcare ecosystem into a connected pathway where every data point delivers impact. The outcome is a faster, smarter, more secure platform for managing enterprise clinical data that drives better outcomes and creates revenue-generating opportunities for our client partners while enhancing security, compliance, and clinical integrity.
With 24 years of trusted solutions and partnerships, MRO knows that a stronger healthcare ecosystem begins with smarter data, leading to data-driven decisions and better performance. Learn more at www.mrocorp.com.
Media Contact:
[email protected]
1.678.956.9680
View original content to download multimedia:https://www.prnewswire.com/news-releases/mro-releases-2026-state-of-the-industry-report-302663088.html
SOURCE MRO
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Invictus Pharmacy and Mullan Pharmaceutical Inc. Announce Strategic Partnership to Expand Patient Access to FDA-Approved Ganirelix Acetate Injection Through Invictus Pharmacy
- Hub Group, Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and Approximately 31% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
- Penny Crypto Worth Watching in 2026: Low-Price Picks and Bullski’s Presale on the Priority List
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share